Prognosis
Pharma Dealmakers, Sidelined in Pandemic, Are Ready for Comeback
- Oncology, rare diseases back in focus after virus turmoil
- Packed hotels out, Zoom in as Covid-19 changes merger tactics
Photographer: Wang Zhao/AFP via Getty Images
This article is for subscribers only.
Bankers and executives flooded an old San Francisco hotel this past January for the drug industry’s premier event for networking, hobnobbing and doing deals.
Six months later, in the middle of the Covid-19 pandemic, the JP Morgan Annual Healthcare Conference, with its crowded panels and presentations, finger food and seas of suits, feels like a distant memory. But that doesn’t mean mergers are dead.